Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial

Blood (2024) 144 (Supplement 1): 3238.

https://doi.org/10.1182/blood-2024-198917

Published: 2024

Journal Articles

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination

Yair Herishanu, Galia Rahav, Shai Levi, Andrei Braester, Gilad Itchaki, Osnat Bairey, Najib Dally, Lev Shvidel, Tomer Ziv-Baran, Aaron Polliack, Tamar Tadmor, Ohad Benjamini, on behalf of the Israeli CLL Study Group

Blood (2022) 139 (5): 678–685.

https://doi.org/10.1182/blood.2021014085

Published: 2022

Includes: Supplemental data

Journal Articles

Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study

Blood (2021) 138 (Supplement 1): 2641.

https://doi.org/10.1182/blood-2021-146848

Published: 2021

Journal Articles

Real-World Efficacy of Venetoclax-Based Regimens in Patients with Chronic Lymphocytic Leukemia in Israel: A Multicenter Prospective Study

Yair Herishanu, Neta Goldschmidt, Gilad Itchaki, Itai Levi, Ariel Aviv, Riva Fineman, Najib Dally, Tamar Tadmor, Rosa Ruchlemer, Uri Abadi, Lev Shvidel, Andrei Braester, Raanan Cohen, Neta Frankel, Keren Ofek, Jenia Berelovich, Moshe Grunspan, Ohad Benjamini

Blood (2021) 138 (Supplement 1): 3727.

https://doi.org/10.1182/blood-2021-146504

Published: 2021

Journal Articles

The Role of Alpha 2 Macroglobulin in Chronic Activation of the Complement System in Patients with Chronic Lymphocytic Leukemia

Naseba Naseraldeen, M.A., Regina Michelis, D.Sc, Masad Barhoum, MD, Judith Chezar, PhD, Tamar Tadmor, MD, Ariel Aviv, MD, Lev Shvidel, MD, Adi Litmanovich, Mona Yuklea, MD, Mona Shehadeh, PhD, Ety Shaoul, PhD, Andrei Braester, MD

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-141198

Published: 2020

Journal Articles

The Risk of Bleeding in Patients Receiving Ibrutinib Combined with Novel Direct Oral Anticoagulants

Michal Ariela Raz, MD, Jon E. Arnason, MD, Osnat Bairey, MD PhD, Lev Shvidel, MD, Ariel Aviv, MD, Sharon Ben Baruch, MD, Chava Perry, MD PhD, Nadav Sarid, MD, David Varon, MD, Ilya Kirgner, MD, Yair Herishanu, MD, Irit Avivi

Blood (2019) 134 (Supplement_1): 4314.

https://doi.org/10.1182/blood-2019-125356

Published: 2019

Journal Articles

Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg

Yair Herishanu, MD, Adir Shaulov, MD, Riva Fineman, MD, Sandra Bašić-Kinda, MD, Ariel Aviv, MD, Ewa Wasik-Szczepanek, MD PhD, Ozren Jaksic, MD PhD, Mihnea Zdrenghea, MD, Uri Greenbaum, MD, Inga Mandac, MD, Martin Simkovic, MD PhD, Marta Morawska, MD, Ohad Benjamini, MD, Martin Spacek, MD, Anatoly Nemets, MD, Osnat Bairey, MD PhD, Andrea Visentin, MD, Rosa Ruchlemer, MD, Luca Laurenti, MD, Oana Stanca Ciocan, MD, Michael Doubek, MD PhD, Lev Shvidel, MD, Nagib Deli, MD, Fatima Miras Calvo, MD, Anne De Meûter, Maria Dimou, MD PhD, Francesca Romana Mauro, MD, Marta Coscia, MD PhD, Horia Bumbea, MD PhD, Szász Róbert, Tamar Tadmor, MD, Odit Gutwein, Massimo Gentile, Lydia Scarfo, MD, Alessandra Tedeschi, MD, Paolo Sportoletti, Eva Gimeno Vázquez, Juan Marquet Palomanes, MD, Sarit Assouline, MD, Maria Papaioannou, Andrei Breaster, MD, Luciano Levato, MD, Michael Gregor, MD, Gian Matteo Rigolin, MD, Javier Loscertales, MD, Angeles Medina Perez, MD, Marten R. Nijziel, MD PhD, Viola Maria Popov, MDPhDMSc, Rosa Collado, MD, Irma Slavutsky, Shai Levi, MSc, Aaron Polliack, MD, Paolo Ghia, MD PhD

Blood (2019) 134 (Supplement_1): 1766.

https://doi.org/10.1182/blood-2019-122309

Published: 2019

Journal Articles

A Novel Risk-Model to Predict Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia Based on Heavy+Light Chain Immunoparesis and Serum Free Light Chain Analysis: Results from the Israeli CLL Study Group

Tamar Tadmor, MD, Andrei Braester, MD, Najib Dally, MD, Ariel Aviv, Yair Herishanu, MD, Mona Yuklea, MD, Lev Shvidel, MD, Naomi Rahimi-Levene, MD, Rosa Ruchlemer, MD, Ariela Arad, MD, Claudia Fogl, MD, Aaron Polliack, MD, Lee Magal, PhD, Kelly Townsend, PhD

Blood (2018) 132 (Supplement 1): 1849.

https://doi.org/10.1182/blood-2018-99-113771

Published: 2018

Journal Articles

Results of a Phase II of Low-Dose Fludarabine and Cyclophosphamide Combined with Standard Dose Rituximab (FCR-LITE) in Elderly, Untreated Patients with Chronic Lymphocytic Leukemia (CLL): The Israeli CLL Study Group Experience

Tamar Tadmor, MD, Yair Herishanu, MD, Andrei Braester, MD, Osnat Bairey, MD, Ariel Aviv, Naomi Rahimi-Levene, MD, Riva Fineman, MD, Itai Levi, MD, Mona Yuklea, MD, Rosa Ruchlemer, MD, Lev Shvidel, MD, Aaron Polliack, MD

Blood (2018) 132 (Supplement 1): 5566.

https://doi.org/10.1182/blood-2018-99-111681

Published: 2018

Journal Articles

Characteristics, Management and Outcome of DLBCL Patients Presenting with Simultaneous Systemic and CNS Disease at Diagnosis - a Retrospective Multicenter Study

Sharon Ben Barouch, MD, Yair Herishanu, MD, Nadav Sarid, MD, Chava Perry, Irit Avivi, MD, Lev Shvidel, MD, Osnat Bairey, MD, Noa Lavi, MD, Netanel A Horowitz, MD, Abraham Avigdor, MD, Neta Goldschmidt, MD, Eyal Lebel, MD, Orit Sofer

Blood (2017) 130 (Supplement 1): 1563.

https://doi.org/10.1182/blood.V130.Suppl_1.1563.1563

Published: 2017

Journal Articles

Clinical Benefit and Improvement of Mitochondrial Function in Low Risk Myelodysplastic Syndrome Treated By Combination Ultra Coenzyme Q10 and L-Carnitine

Kalman Filanovsky, Michal Haran, MD, Vita Mirkin, PhD, Andrei Braester, MD, Olga Shvetz, MD, Anfisa Stanevsky, MD, Erica Sigler, MD, Ekaterina Votinov, MD, Yehudit Zaltsman-Amir, PhD, Atan Gross, PhD, Lev Shvidel, MD

Blood (2017) 130 (Supplement 1): 1704.

https://doi.org/10.1182/blood.V130.Suppl_1.1704.1704

Published: 2017

Journal Articles

Primary Splenic Diffuse Large B-Cell Lymphoma (PS-DLBCL): Splenectomy Improves Survival

Osnat Bairey, MD, Lev Shvidel, MD, Chava Perry, MD PhD, Eldad J Dann, MD, Rosa Ruchlemer, MD, Tamar Tadmor, MD, Neta Goldschmidt, MD

Blood (2014) 124 (21): 4439.

https://doi.org/10.1182/blood.V124.21.4439.4439

Published: 2014

Journal Articles

Cancer Registries Often Underestimate the True Incidence of CLL

Rosa Ruchlemer, MD, Miri Zatlawi, Yehudit Fishler, Rita Dichtiar, Barbara Silverman, MD MPH, Ariel Aviv, MD, Ariella Arad, MD, Osnat Bairey, MD, Ohad Binyamini, MD, Andre Braester, MD, Riva Fineman, MD, Neta Goldshmidt, MD, Yair Herishanu, MD, Naomi Rahimi-Levene, Lev Shvidel, MD, Tamar Tadmor, MD, Mona Yuklea, MD, Aaron Polliack, MD, Lital Keinan-Boker, MD PhD MPH

Blood (2014) 124 (21): 5646.

https://doi.org/10.1182/blood.V124.21.5646.5646

Published: 2014

Journal Articles

Efficacy and Safety of Frontline Therapy with "FCR" Regimen for Chronic Lymphocytic Leukemia Outside Clinical Trials: Israeli CLL Study Group Experience

Yair Herishanu, MD, Neta Goldschmidt, MD, Osnat Bairey, MD, Rosa Ruchlemer, MD, Riva Fineman, MD, Naomi Rahimi-Levene, Lev Shvidel, MD, Tamar Tadmor, MD, Ariel Aviv, MD, Andrei Braester, MD, Erel Joffe, MDMSc, Aaron Polliack, MD

Blood (2014) 124 (21): 5659.

https://doi.org/10.1182/blood.V124.21.5659.5659

Published: 2014

Journal Articles

Richter’s Syndrome In Chronic Lymphocytic Leukemia: Clinical and Laboratory Features In 119 Patients, Attempting To Identify Possible Risk Factors

Tamar Tadmor, MD, Riva Fineman, MD, Lev Shvidel, Osnat Bairey, MD, Neta Goldschmidt, MD, Rosa Ruchlemer, Naomi Rahimi Rachimi, MD, Yair Herishanu, MD, Mona Yuklea, MD,, Ariela Arad, MD, Ariel Aviv, MD, Aaron Polliack, MD

Blood (2013) 122 (21): 5281.

https://doi.org/10.1182/blood.V122.21.5281.5281

Published: 2013

Journal Articles

Presenting Features and Outcome of Elderly Chronic Lymphocytic Leukemia Patients Diagnosed at the Age of 80 Years or Above. An ICLLSG Study.

Osnat Bairey, Rosa Ruchlemer, MD, Naomi Rahimi-Levene, Yair Herishanu, MD, Andrei Braester, MD, Abraham Klepfish, MD, Lev Shvidel

Blood (2010) 116 (21): 4620.

https://doi.org/10.1182/blood.V116.21.4620.4620

Published: 2010

Journal Articles

Evaluation of Novel S-Allyl Derivatives of 6-Mercapto-Purine against B-CLL: Combining the Effects of Different Compounds in A Single Molecule.

Fabian David Arditti, PhD, Mordechai Shtalrid, MD, Lucette Bassous, Lev Shvidel, MD, Alain Berrebi, MD, Talia Miron, PhD

Blood (2009) 114 (22): 3437.

https://doi.org/10.1182/blood.V114.22.3437.3437

Published: 2009

Journal Articles

The Significance of Elevated Beta 2-Microglobulin (b2-m) in B-CLL: Evidence of in Vitro b2-m Secretion Following Activation of B-CLL Cells.

Alain Berrebi, MD, Lev Shvidel, MD, Fabian David Arditti, PhD, Lucette Bassous, Michal Haran, Mordechai Shtalrid, MD

Blood (2009) 114 (22): 4380.

https://doi.org/10.1182/blood.V114.22.4380.4380

Published: 2009

Journal Articles

Chromosomal Abnormalities Detected by FISH in CLL May Be Influenced by Ethnic Origin: Preliminary Data from a Multicenter Study in Israel for the Israel CLL Study Group (ICLLSG).

Rosa Ruchlemer, MD, Lev Shvidel, MD, Andre A. Baester, MD, Osnat Bairey, MD, Alain Berrebi, MD, Aaron Polliack, MD

Blood (2007) 110 (11): 4705.

https://doi.org/10.1182/blood.V110.11.4705.4705

Published: 2007

Journal Articles

Predictive Factors to Hypogammaglobulinemia and Non-Neutropenic Infection Complications after Rituximab/Chemotherapy Treatment

Kalman Filanovsky, MD, Lev Shvidel, MD, Mordechai Shtalrid, MD, Michal Haran, MD, Adrian Duek, MD, Alain Berrebi

Blood (2007) 110 (11): 1288.

https://doi.org/10.1182/blood.V110.11.1288.1288

Published: 2007

NARROW

Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination

Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study

Real-World Efficacy of Venetoclax-Based Regimens in Patients with Chronic Lymphocytic Leukemia in Israel: A Multicenter Prospective Study

The Role of Alpha 2 Macroglobulin in Chronic Activation of the Complement System in Patients with Chronic Lymphocytic Leukemia

The Risk of Bleeding in Patients Receiving Ibrutinib Combined with Novel Direct Oral Anticoagulants

Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg

A Novel Risk-Model to Predict Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia Based on Heavy+Light Chain Immunoparesis and Serum Free Light Chain Analysis: Results from the Israeli CLL Study Group

Results of a Phase II of Low-Dose Fludarabine and Cyclophosphamide Combined with Standard Dose Rituximab (FCR-LITE) in Elderly, Untreated Patients with Chronic Lymphocytic Leukemia (CLL): The Israeli CLL Study Group Experience

Characteristics, Management and Outcome of DLBCL Patients Presenting with Simultaneous Systemic and CNS Disease at Diagnosis - a Retrospective Multicenter Study

Clinical Benefit and Improvement of Mitochondrial Function in Low Risk Myelodysplastic Syndrome Treated By Combination Ultra Coenzyme Q10 and L-Carnitine

Primary Splenic Diffuse Large B-Cell Lymphoma (PS-DLBCL): Splenectomy Improves Survival

Cancer Registries Often Underestimate the True Incidence of CLL

Efficacy and Safety of Frontline Therapy with "FCR" Regimen for Chronic Lymphocytic Leukemia Outside Clinical Trials: Israeli CLL Study Group Experience

Richter’s Syndrome In Chronic Lymphocytic Leukemia: Clinical and Laboratory Features In 119 Patients, Attempting To Identify Possible Risk Factors

Presenting Features and Outcome of Elderly Chronic Lymphocytic Leukemia Patients Diagnosed at the Age of 80 Years or Above. An ICLLSG Study.

Evaluation of Novel S-Allyl Derivatives of 6-Mercapto-Purine against B-CLL: Combining the Effects of Different Compounds in A Single Molecule.

The Significance of Elevated Beta 2-Microglobulin (b2-m) in B-CLL: Evidence of in Vitro b2-m Secretion Following Activation of B-CLL Cells.

Chromosomal Abnormalities Detected by FISH in CLL May Be Influenced by Ethnic Origin: Preliminary Data from a Multicenter Study in Israel for the Israel CLL Study Group (ICLLSG).

Predictive Factors to Hypogammaglobulinemia and Non-Neutropenic Infection Complications after Rituximab/Chemotherapy Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only